CMAJ • January 17, 2006; 174 (2). doi:10.1503/cmaj.050748.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v174,p1874)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simpson, S. H.
Right arrow Articles by Johnson, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpson, S. H.
Right arrow Articles by Johnson, J. A.
Related Collections
Right arrow Drugs: cardiovascular system
Right arrow Diabetes
Right arrowRelated Article

Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

Scot H. Simpson, Sumit R. Majumdar, Ross T. Tsuyuki, Dean T. Eurich and Jeffrey A. Johnson

From the Institute of Health Economics (all authors); the Faculty of Pharmacy and Pharmaceutical Sciences (Simpson, Tsuyuki); the Divisions of General Internal Medicine (Majumdar) and Cardiology (Tsuyuki), Department of Medicine; and the Department of Public Health Sciences (Majumdar, Tsuyuki, Eurich, Johnson), University of Alberta, Edmonton, Alta.


View this table:

[in a new window]
  		Table 1.

 

Figure 116
View larger version (20K):

[in a new window]
  		Fig. 1: Hazard ratios among patients with type 2 diabetes mellitus, comparing 2 subgroups within each drug-monotherapy group: 1A, hazard ratios for deaths from all causes, according to median split for drug exposure (i.e., whether their individual daily dose was more than the group median [higher subgroup] or less [lower subgroup — used as the reference]); 1B, for deaths attributable to an acute ischemic event, also according to median split for drug exposure; and 1C, for all-cause mortality, according to drug-treatment adherence (patients were assigned to the poor-adherence [reference] subgroup if their adherence rate was < 0.8 or if they stopped therapy > 6 months before end of follow-up). Error bars indicate 95% confidence intervals. *Either chlorpropamide or tolbutamide.